178 related articles for article (PubMed ID: 36760024)
1. Dopamine agonists and risk of lung cancer in patients with restless legs syndrome.
Hernandez-Con P; Shults J; Willis AW; Yang YX
Pharmacoepidemiol Drug Saf; 2023 Jul; 32(7):726-734. PubMed ID: 36760024
[TBL] [Abstract][Full Text] [Related]
2. Increased Risk for New-Onset Psychiatric Adverse Events in Patients With Newly Diagnosed Primary Restless Legs Syndrome Who Initiate Treatment With Dopamine Agonists: A Large-Scale Retrospective Claims Matched-Cohort Analysis.
Hankin C; Lee D; Garcia-Borreguero D; Wang Z
J Clin Sleep Med; 2019 Sep; 15(9):1225-1232. PubMed ID: 31538593
[TBL] [Abstract][Full Text] [Related]
3. Risk of Cardiovascular Disease Associated with a Restless Legs Syndrome Diagnosis in a Retrospective Cohort Study from Kaiser Permanente Northern California.
Van Den Eeden SK; Albers KB; Davidson JE; Kushida CA; Leimpeter AD; Nelson LM; Popat R; Tanner CM; Bibeau K; Quesenberry CP
Sleep; 2015 Jul; 38(7):1009-15. PubMed ID: 26083613
[TBL] [Abstract][Full Text] [Related]
4. High national rates of high-dose dopamine agonist prescribing for restless legs syndrome.
Winkelman JW
Sleep; 2022 Feb; 45(2):. PubMed ID: 34417810
[TBL] [Abstract][Full Text] [Related]
5. Use of antidepressants and risks of restless legs syndrome in patients with irritable bowel syndrome: A population-based cohort study.
Hsu YC; Yang HY; Huang WT; Chen SC; Lee HS
PLoS One; 2019; 14(8):e0220641. PubMed ID: 31369638
[TBL] [Abstract][Full Text] [Related]
6. Incident mental health episodes after initiation of gabapentinoids vs. dopamine agonists for early-onset idiopathic restless legs syndrome.
Costales B; Vouri SM; Brown JD; Setlow B; Goodin AJ
Psychiatry Res; 2023 Oct; 328():115479. PubMed ID: 37708806
[TBL] [Abstract][Full Text] [Related]
7. Long-term Safety, Dose Stability, and Efficacy of Opioids for Patients With Restless Legs Syndrome in the National RLS Opioid Registry.
Winkelman JW; Wipper B; Zackon J
Neurology; 2023 Apr; 100(14):e1520-e1528. PubMed ID: 36697248
[TBL] [Abstract][Full Text] [Related]
8. Decline in dopamine agonists prescribing and characteristics of drugs prescribed during ambulatory office visits for restless legs syndrome: the National Ambulatory Medical Care Survey 2007-2015.
Kim J; Hartzema AG
Sleep Med; 2019 Feb; 54():238-243. PubMed ID: 30590306
[TBL] [Abstract][Full Text] [Related]
9. Health care resource utilization and costs associated with restless legs syndrome among managed care enrollees treated with dopamine agonists.
Meyers J; Candrilli S; Allen R; Manjunath R; Calloway M
Manag Care; 2012 Oct; 21(10):44-51. PubMed ID: 23156076
[TBL] [Abstract][Full Text] [Related]
10. Frequency of impulse control behaviours associated with dopaminergic therapy in restless legs syndrome.
Voon V; Schoerling A; Wenzel S; Ekanayake V; Reiff J; Trenkwalder C; Sixel-Döring F
BMC Neurol; 2011 Sep; 11():117. PubMed ID: 21955669
[TBL] [Abstract][Full Text] [Related]
11. Association of Restless Legs Syndrome With Incident Parkinson's Disease.
Szatmari S; Bereczki D; Fornadi K; Kalantar-Zadeh K; Kovesdy CP; Molnar MZ
Sleep; 2017 Feb; 40(2):. PubMed ID: 28364505
[TBL] [Abstract][Full Text] [Related]
12. An exploratory retrospective evaluation of ropinirole-associated psychotic symptoms in an outpatient population treated for restless legs syndrome or Parkinson's disease.
Stoner SC; Dahmen MM; Makos M; Lea JW; Carver LJ; Rasu RS
Ann Pharmacother; 2009 Sep; 43(9):1426-32. PubMed ID: 19690226
[TBL] [Abstract][Full Text] [Related]
13. Restless leg syndrome and risk of all-cause dementia: a nationwide retrospective cohort study.
Kim KY; Kim EH; Lee M; Ha J; Jung I; Kim E
Alzheimers Res Ther; 2023 Mar; 15(1):46. PubMed ID: 36879327
[TBL] [Abstract][Full Text] [Related]
14. Iron for the treatment of restless legs syndrome.
Trotti LM; Becker LA
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD007834. PubMed ID: 30609006
[TBL] [Abstract][Full Text] [Related]
15. Compulsive habits in restless legs syndrome patients under dopaminergic treatment.
Pourcher E; Rémillard S; Cohen H
J Neurol Sci; 2010 Mar; 290(1-2):52-6. PubMed ID: 19969309
[TBL] [Abstract][Full Text] [Related]
16. Decision-making, reward-seeking behaviors and dopamine agonist therapy in restless legs syndrome.
Bayard S; Langenier MC; Dauvilliers Y
Sleep; 2013 Oct; 36(10):1501-7. PubMed ID: 24082309
[TBL] [Abstract][Full Text] [Related]
17. Long-term treatment of restless legs syndrome with dopamine agonists.
Ondo W; Romanyshyn J; Vuong KD; Lai D
Arch Neurol; 2004 Sep; 61(9):1393-7. PubMed ID: 15364685
[TBL] [Abstract][Full Text] [Related]
18. From bench to bedside: An overview of rotigotine for the treatment of restless legs syndrome.
Bogan RK
Clin Ther; 2014 Mar; 36(3):436-55. PubMed ID: 24636821
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute.
García-Borreguero D; Allen RP; Kohnen R; Högl B; Trenkwalder C; Oertel W; Hening WA; Paulus W; Rye D; Walters A; Winkelmann J; Earley CJ;
Sleep Med; 2007 Aug; 8(5):520-30. PubMed ID: 17544323
[TBL] [Abstract][Full Text] [Related]
20. A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome.
Silver N; Allen RP; Senerth J; Earley CJ
Sleep Med; 2011 May; 12(5):440-4. PubMed ID: 21239226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
